Complexa Inc. is a clinical stage biopharmaceutical company focused on transforming the treatment of fibrosis and inflammation-associated orphan diseases. Leveraging its differentiated endogenous nitrated fatty acid cell signaling technology, Complexa is advancing a platform of agents which target fibrosis and inflammation across multiple orphan disease indications. Complexa's initial disease focus is on FSGS and PAH, and development of other new chemical entities in its platform of cell signaling compounds.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/26/17 | $62,000,000 | Series C |
Edmond de Rothschild Investment Partners HBM Healthcare Investments JAFCO Pfizer Strategic Investments Group  | undisclosed |
